BioSpace News Archive

According to Transparency Market Research’s latest report on the global collagen peptide and gelatin market for the historical period 2017–2018 and forecast period 2019–2027, increase in commercialization of novel collagen-based drug delivery systems and rise in social awareness about personal well-being are projected to drive the global collagen peptide and gelatin market.

Tissue engineered skin substitutes or artificial skin substitutes can be defined as bioengineered skin substitutes derived from human tissue, non-human tissue, synthetic materials, and composite of these materials.

I-Mab announced that it has entered into a strategic collaboration agreement with Jumpcan Pharmaceutical Group, a leading China pharmaceutical company specialized in and committed to pediatric medicines, for the development, manufacturing and commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China.

SOMAÍ Pharmaceuticals Unipessoal LDA has received an innovative products grant of 2.7 million euros by the Portugal 2020 committee.

Encision Inc., a medical device company owning patented Active Electrode Monitoring Technology that prevents dangerous radiant energy burns in minimally invasive surgery, announced financial results for its fiscal 2022 second quarter that ended September 30, 2021.

BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced that it has appointed Robert Kristal to the position of Chief Financial Officer.

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients, reported its financial results for the third quarter ended September 30, 2021 and provided a business update.

Nuvalent, Inc. today reported recent pipeline progress and third quarter 2021 financial results.

Taiga Biotechnologies announced today that the Company has completed the site initiation session for the first site to participate in the TBX-2400-01 clinical trial, a Phase 1/2 study to evaluate the safety and early efficacy of TBX-2400 in acute myeloid leukemia (AML) and myelofibrosis patients undergoing hematopoietic stem cell transplant (HSCT), in Croatia.

The drive for molecular biology enzymes, kits and reagents, stems from steady strides being made in life sciences industry.